New treatment may lead the way to fighting obesity and diabetes

April 25, 2013, CORDIS
New treatment may lead the way to fighting obesity and diabetes
Credit: Shutterstock

Two professors believe they may have a promising lead from which to develop a new treatment for obesity and diabetes.

The project titled i2MOVE ('Intelligent implantable modulator of vagus for treatment of obesity') is being led by two Imperial College London Professors: Christofer Toumazou from the Department of Electrical and , and Sir Stephen Bloom from the Department of Medicine. The Professors' combined expertise in and endocrinology is leading the way in creating a device that mimics the response of the vagus nerve, which connects the brain to everything from the tongue, pharynx, , lungs, heart, stomach and intestines. Their device is designed to suppress the appetite of a patient.

With a starting grant from the European Research Council (ERC) of over EUR 7 million, the four-year project is already making headway. They have so far developed a hormone combination using and glucagon-like peptide 1 (GLP-1), which plays a key role in regulating and helps reduce appetite. This may form the basis for a new treatment for obesity and diabetes in the future.

Glucagon works in opposition to insulin, preventing the storage of glucose in fat deposits and the liver, and raising blood sugar levels. GLP-1 stimulates the release of insulin to lower blood sugar and also acts on the brain to reduce appetite.

Fighting obesity is the main objective of the project, a condition considered by the (WHO) as one of the greatest public health challenges of the 21st century. Over 23 % of Europeans are regarded as obese and the health costs alone accounted for more than 10 billion EUR in 2010. Existing treatments such as surgery are deemed to be rarely effective, which is why the i2MOVE research team believes that of the Vagus nerve could be efficient when combined with intelligent recording. This is an intelligent' implant which records vagal signals associated with hormone release during eating. This is designed to stimulate the nerve to modulate these signals to better regulate appetite.

Professor Bloom, together with his research team, set out to identify whether glucagon and GLP-1 infused into the blood might work together to reduce appetite. In his study, 16 volunteers were given a sequence of four treatments: glucagon, GLP-1, glucagon and GLP-1 in combination, and saline as a control. The order of the treatments was determined at random. Each treatment was then given via a drip over a period of two hours. After the first hour and a half, each volunteer was offered a meal. Researchers recorded how much they ate and measured their energy expenditure and levels. The results revealed that subjects ate 13 % fewer calories after being given the two hormones in combination compared with saline, but no significant difference was detected after taking either hormone on its own.

Volunteers treated with a glucagon/GLP-1 combination consumed significantly less food, according to Professor Bloom. These results replicate the team's findings in animals, suggesting that a glucagon/GLP-1 combination may be a promising lead from which to develop a new treatment for obesity and diabetes.

'Thirteen per cent is a big reduction in food intake by anyone's standards, but our experiment is only an appetiser' he stresses. 'An effective future treatment will need to suppress appetite in the long term, so we next aim to establish whether the effects can be sustained to lead to real weight loss.'

Explore further: Gut hormone leads to weight loss in overweight or obese patients

Related Stories

Gut hormone leads to weight loss in overweight or obese patients

January 10, 2012
Giving overweight or obese patients a gut hormone that suppresses appetite leads to clinically beneficial weight loss as well as reduced blood pressure and cholesterol levels, finds a study published in the British Medical ...

Research reveals hormone action that could lead to treatments for type 2 diabetes

September 30, 2011
(Medical Xpress) -- Researchers at the University of Cincinnati have discovered that the immediate improvement in blood sugar (blood glucose) for those with type 2 diabetes who undergo gastric bypass surgery is related to ...

Importance of diabetes genetic variants unclear

April 4, 2012
(HealthDay) -- Genetic variants associated with type 2 diabetes that affect glucagon-like peptide 1 (GLP-1) are not associated with GLP-1 levels or GLP-1-induced insulin secretion in healthy individuals, according to a study ...

High-fat diet impairs satiation signaling in obese-prone

February 27, 2013
(HealthDay)—Feeding obese-prone rats a high-fat diet leads to impaired satiation signaling through glucagon-like peptide-1 (GLP-1), a gastrointestinal hormone that suppresses food intake and helps regulate energy balance, ...

New inflammation hormone link may pave way to study new drugs for Type 2 diabetes

May 15, 2012
A new link between obesity and type 2 diabetes found in mice could open the door to exploring new potential drug treatments for diabetes, University of Michigan Health System research has found.

Simple gut hormone combo makes our brains think we're full

October 25, 2011
Many of us would love nothing more than to trick ourselves into believing we are full even as our stomachs remain empty. Now, a new brain imaging study reported in the November issue of the Cell Press journal Cell Metabolism ...

Recommended for you

Evening hours may pose higher risk for overeating, especially when under stress, study finds

January 16, 2018
Experiments with a small group of overweight men and women have added to evidence that "hunger hormone" levels rise and "satiety (or fullness) hormone" levels decrease in the evening. The findings also suggest that stress ...

Bariatric surgery prolongs lifespan in obese

January 16, 2018
Obese, middle-age men and women who had bariatric surgery have half the death rate of those who had traditional medical treatment over a 10-year period, reports a study that answers questions about the long-term risk of the ...

Sugar-sweetened drinks linked to overweight and obesity in children, adults: Analysis of new studies

December 23, 2017
A new review of the latest evidence on sugar-sweetened beverages (SSBs)- which includes 30 new studies published between 2013 and 2015 (and none of them industry sponsored) - concludes that SSB consumption is associated with ...

As income rises, women get slimmer—but not men

December 21, 2017
(HealthDay)—A comprehensive survey on the widening American waistline finds that as paychecks get bigger, women's average weight tends to drop.

Policy and early intervention can curb obesity rates

December 18, 2017
More information and emphasis on dietary lifestyle changes that prevent obesity, and its comorbidities, have not reduced the rise in obesity in U.S. adults and adolescents, according to a recent study in the New England Journal ...

Warning labels can help reduce soda consumption and obesity, new study suggests

December 15, 2017
Labels that warn people about the risks of drinking soda and other sugar-sweetened beverages can lower obesity and overweight prevalence, suggests a new Johns Hopkins Bloomberg School of Public Health study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.